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Variables 0 1 2 3 4 
Respiratory 
PaO2/FIO2,mmHg 
>400 ≤400 ≤300 ≤200 ≤100 
Coagulation 
Platelets	x	10^3/ul 
>150 ≤150 ≤100 ≤50 ≤20 
Liver 
Bilirubin,	mg/dl 














































































































Overview of Studies Included in Review 
 Study 1: Marik et al Study 2: Zabet et al Study 3: Habib et al 
Year published 2016 2016 2017 
Sample Size 94 28 100 
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Zabet Died Survived NNT	=	2 
Vitamin	C	Treatment	Group 2 12 
Control	Group 9 5 
Habib Did	Not	Survive Survived NNT	=	8 
Vitamin	C	Treatment	Group 12 38 
Control	Group 18 32 
Combined	Studies	Overall Did	Not	Survive Survived NNT	=	5 
Vitamin	C	Treatment	Groups 14 50 
Control	Groups 27 37 
Table	9.	Number	needed	to	treat	based	on	mortality	data	for	each	study	and	the	combined	number	
to	treat.	The	Marik	et	al	study	was	not	included	due	to	study	design.	 
 
DISCUSSION 
	 Sepsis	is	the	result	of	a	systemic	infection	and	is	a	major	health	concern	with	
considerable	associated	morbidity	and	mortality.	The	massive	vasodilatory	response	to	the	
infection	results	in	poor	perfusion	of	organs	and	tissues	leading	to	multi	organ	system	
damage.	Current	therapies	are	aimed	at	treating	the	infection	in	addition	to	maintaining	
adequate	perfusion.		This	is	accomplished	by	using	broad-spectrum	antibiotics,	fluid	
resuscitation,	and	vasopressors	to	maintain	a	mean	arterial	pressure	of	greater	than	65	
mmHg.	Recently	there	has	been	interest	in	the	addition	of	Vitamin	C	to	the	standard	
treatment	of	septic	shock.	The	aim	of	this	review	was	to	investigate	the	role	of	Vitamin	C	in	
the	treatment	of	septic	shock	by	analyzing	three	recent	studies	that	compared	Vitamin	C	
usage	to	standard	treatment.		Each	of	these	studies	compared	the	efficacy	of	adding	Vitamin	
C	to	standard	treatments	by	using	vasopressor	requirements,	length	of	ICU	stay,	and	
mortality	as	comparable	outcomes.	An	overview	of	the	findings	of	the	studies	in	this	review	
is	provided	in	Table	3.	 
All	three	studies	demonstrated	a	significant	reduction	in	vasopressor	dependency	
within	the	Vitamin	C	treatment	group.		This	outcome	is	not	surprising	as	ascorbic	acid	is	a	
cofactor	for	the	enzymes	involved	in	the	synthesis	of	endogenous	vasopressors.		Sepsis	
results	in	significant	oxidative	stress	resulting	in	a	reduction	of	Vitamin	C	levels	and	
therefore	a	reduction	in	the	synthesis	of	norepinephrine	and	vasopressin.		This	is	a	
significant	finding,	however,	based	on	these	articles	alone	it	is	unclear	whether	the	
reduction	in	vasopressor	dependency	is	associated	with	a	decrease	in	mortality. 
There	was	conflicting	evidence	among	the	studies	regarding	the	duration	of	ICU	stay	
and	reduction	of	mortality	in	the	Vitamin	C	treatment	group.	Marik	et	al	and	Zabet	et	al	
found	that	the	addition	of	Vitamin	C	to	standard	sepsis	treatment	resulted	in	a	statistically	
significant	reduction	in	mortality,	with	p	values	of	0.001	and	0.009	respectively.		Although	
Marik	et	al.	did	show	a	statistically	significant	reduction	in	mortality,	due	to	the	low	power	
of	the	study	and	it’s	quasi-experimental	design,	it	is	difficult	to	determine	the	validity	of	this	
result.			Habib	et	al	found	no	statistically	significant	difference	in	mortality	with	the	addition	
of	Vitamin	C,	with	a	p	value	of	0.138.		These	conflicting	results	could	be	due	to	the	low	
power	of	all	three	studies.		 
The	most	notable	limitation	to	this	review	is	the	low	power	within	each	of	the	
studies.		The	small	sample	size	in	these	trials	and	lack	of	significant	randomized	controlled	
trials	on	this	topic	are	likely	due	the	lack	of	knowledge	about	adverse	effects	associated	
with	the	addition	of	Vitamin	C	in	septic	shock.		A	recent	Phase	1	safety	trial	was	conducted	
in	2014	by	Fowler	et	al	to	examine	the	safety	of	Vitamin	C	in	the	treatment	of	sepsis.		The	
results	found	by	this	trial	demonstrated	that	the	addition	of	Vitamin	C	in	septic	shock	was	
safe	and	well	tolerated	with	no	adverse	events.16	With	these	results	and	the	promising	
results	found	in	the	three	studies	in	this	review,	there	will	hopefully	be	larger	randomized	
controlled	trials	conducted	in	the	future	to	reveal	more	conclusive	outcomes	for	the	use	of	
Vitamin	C	therapy	in	septic	shock. 
Number	needed	to	treat	(NNT)	is	a	metric	used	to	assess	the	impact	of	a	therapy.	It	
is	the	number	of	patients	that	must	be	treated	for	one	patient	to	benefit	from	the	therapy	
over	a	specified	time.	Calculated	from	mortality	data	in	Table	9,	the	NNT	for	the	Zabet	et	al	
study	was	2.	This	means	that	for	every	2	patients	with	septic	shock	treated	with	the	
regimen	in	Table	8	for	72	hours,	there	was	a	patient	who	had	a	reduced	28	day	mortality.	
For	the	Habib	et	al	study,	the	NNT	was	8,	meaning	that	for	every	8	patients	treated	with	the	
regimen	in	Table	8	for	24	hours	after	ICU	admission,	there	was	a	patient	who	had	reduced	
ICU	mortality.	The	NNT	was	not	calculated	for	the	Marik	study	due	to	this	study	being	a	
before-and-after	study	and	not	a	randomized	controlled	clinical	trial.	Combining	the	
mortality	data	from	the	Zabet	and	Habib	studies	results	in	an	NNT	of	5	(Table	9).	The	NNT	
measure	does	require	that	the	studies	be	equivalent	in	the	duration	of	time	for	which	the	
outcome	is	observed.	The	Habib	et	al	study	does	not	include	enough	information	on	the	
mortality	outcome	measure	to	assure	equivalence	in	time.	Therefore	these	studies	may	not	
be	directly	comparable	by	using	the	NNT	measure.	Nevertheless,	the	NNT	measures	from	
these	studies	individually	and	combined	do	suggest	possible	benefit	in	the	treatment	of	
septic	shock,	a	condition	which	has	a	very	poor	prognosis	
	
CONCLUSION 
These	studies	appear	to	demonstrate	improvements	in	patient	outcomes	when	
standard	treatments	of	septic	shock	are	supplemented	with	high	doses	of	Vitamin	C.	Each	of	
the	studies	assessed	indicates	a	significant	reduction	in	vasopressor	requirements	for	septic	
patients	when	they	are	treated	with	high	doses	of	Vitamin	C	as	adjunct	therapy	to	standard	
treatment.	Two	of	the	three	studies	showed	a	significant	reduction	in	mortality.	These	
studies	suffer	from	small	sample	sizes,	and	only	two	of	them	are	randomized	controlled	
trials.	Considerations	for	future	studies	include	the	measurement	of	Vitamin	C	levels	prior	
to	and	during	treatment	and	the	comparison	of	SOFA	scores	between	the	treatment	and	
control	groups.	If	the	results	of	these	studies	can	be	replicated	in	large	scale	randomized	
controlled	trials,	certainly	there	would	be	a	case	for	Vitamin	C	to	be	included	in	the	
standard	treatment	of	septic	shock. 
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